Correction: Novel protein-based prognostic signature linked to immunotherapeutic efficiency in ovarian cancer.
作者信息
Chen Shuo-Fu, Wang Liang-Yun, Lin Yi-Sian, Chen Cho-Yi
机构信息
Department of Heavy Particles & Radiation Oncology, Taipei Veterans General Hospital, Taipei, 112, Taiwan.
Institute of Biomedical Informatics, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.
出版信息
J Ovarian Res. 2025 Jan 28;18(1):15. doi: 10.1186/s13048-025-01605-6.
Abstract
摘要
相似文献
1
Correction: Novel protein-based prognostic signature linked to immunotherapeutic efficiency in ovarian cancer.更正：与卵巢癌免疫治疗疗效相关的基于蛋白质的新型预后标志物。
J Ovarian Res. 2025 Jan 28;18(1):15. doi: 10.1186/s13048-025-01605-6.
2
Novel protein-based prognostic signature linked to immunotherapeutic efficiency in ovarian cancer.新型蛋白预后标志物与卵巢癌免疫治疗疗效相关。
J Ovarian Res. 2024 Sep 28;17(1):190. doi: 10.1186/s13048-024-01518-w.
3
Transcriptomic characterization and construction of M2 macrophage-related prognostic and immunotherapeutic signature in ovarian metastasis of gastric cancer.胃癌卵巢转移中 M2 巨噬细胞相关预后和免疫治疗特征的转录组学特征分析与构建。
Cancer Immunol Immunother. 2023 May;72(5):1121-1138. doi: 10.1007/s00262-022-03316-z. Epub 2022 Nov 7.
4
Development of a Novel Immune-Related Gene Signature to Predict Prognosis and Immunotherapeutic Efficiency in Gastric Cancer.开发一种新型免疫相关基因特征以预测胃癌预后和免疫治疗效果
Front Genet. 2022 May 27;13:885553. doi: 10.3389/fgene.2022.885553. eCollection 2022.
5
Suppressive stroma-immune prognostic signature impedes immunotherapy in ovarian cancer and can be reversed by PDGFRB inhibitors.抑制性基质-免疫预后标志物阻碍卵巢癌的免疫治疗，并可被 PDGFRB 抑制剂逆转。
J Transl Med. 2023 Sep 1;21(1):586. doi: 10.1186/s12967-023-04422-x.
6
Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma.基于蛋白质的预后标志物，用于预测子宫内膜癌的生存和免疫治疗效果。
BMC Cancer. 2022 Mar 25;22(1):325. doi: 10.1186/s12885-022-09402-w.
7
Correction: Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma.更正：用于预测子宫内膜癌生存及免疫治疗疗效的基于蛋白质的预后特征。
BMC Cancer. 2022 May 2;22(1):480. doi: 10.1186/s12885-022-09517-0.
8
Development of a Novel Autophagy-related Prognostic Signature for Serous Ovarian Cancer.一种用于浆液性卵巢癌的新型自噬相关预后标志物的开发。
J Cancer. 2018 Oct 18;9(21):4058-4071. doi: 10.7150/jca.25587. eCollection 2018.
9
Development and Validation of an Immune-Related Prognostic Signature for Ovarian Cancer Based on Weighted Gene Coexpression Network Analysis.基于加权基因共表达网络分析的卵巢癌免疫相关预后signature 的建立和验证。
Biomed Res Int. 2020 Dec 10;2020:7594098. doi: 10.1155/2020/7594098. eCollection 2020.
10
Identification and Validation of Immune-Related Long Non-Coding RNA Signature for Predicting Immunotherapeutic Response and Prognosis in NSCLC Patients Treated With Immunotherapy.用于预测接受免疫治疗的非小细胞肺癌患者免疫治疗反应和预后的免疫相关长链非编码RNA特征的鉴定与验证
Front Oncol. 2022 Jul 4;12:899925. doi: 10.3389/fonc.2022.899925. eCollection 2022.
本文引用的文献
1
Novel protein-based prognostic signature linked to immunotherapeutic efficiency in ovarian cancer.新型蛋白预后标志物与卵巢癌免疫治疗疗效相关。
J Ovarian Res. 2024 Sep 28;17(1):190. doi: 10.1186/s13048-024-01518-w.
Zotero 插件